SPARC promoters seek reclassification of 1.85% stake to public category
NiveshIQ
NSE: SPARC · Pharma
Sun Pharma Advanced Research Company Ltd.
₹213.17▲ ₹4.21 (+2.01%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on SPARC. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Sun Pharma Advanced Research Company Ltd.
Sun Pharma Advanced Research Company Limited (SPARC) is a clinical-stage biopharmaceutical company focused on developing pharmaceutical products in oncology and immunology. The company has a pipeline of products, including Vodobatinib (SCO-088) and Vibozilimod (SCD-044), which are in phase 2 clinical trials for the treatment of refractory chronic myelogenous leukemia and psoriasis/atopic dermatitis, respectively. Additionally, SPARC is developing SCD-153 for alopecia areata and SBO-154, an anti-MUC-1 ADC, for multiple tumors. The company reported a massive profit in FY26, driven by the sale of a USD 195 million priority review voucher. SPARC's revenue stood at ₹53 Cr, while net income was ₹-268 Cr. The company's pipeline and recent financial performance indicate its potential for growth in
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹76.00 Cr -68.20% | ₹71.77 Cr -5.60% | ₹1,879 Cr +2518.30% |
| EBITDA Margin | -528.95% | -447.75% | 85.66% |
| Net Profit | ₹1,566 Cr | ||
| EPS | ₹-11.93 | ₹-10.55 | ₹47.86 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Price to sales forward of Sun Pharma Advanced Research Co. Ltd. – NSE:SPARC
Sun Pharma Advanced Research Co. Ltd. Revenue Breakdown – NSE:SPARC
🔒
+ 3 more stories about Sun Pharma Advanced Research Company Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹1, 853 Cr, PAT ₹1, 761 Cr, EPS ₹54.27, EBITDA margin 95.8%. Growth context: revenue QoQ +23065.2%, PAT QoQ -2301.7%.
Recent corporate activity highlights R&D investments and technology initiatives as the primary near-term growth lever, w...
FY26 (last completed FY): revenue ₹1, 879 Cr, PAT ₹1, 566 Cr, EBITDA margin 85.7%, EPS ₹47.86. Year-on-year: revenue YoY...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for SPARC
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track SPARC alongside your other holdings
Unlock full SPARC research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Sun Pharma Advanced Research Company Ltd.?
NiveshIQ detects active intelligence signals for Sun Pharma Advanced Research Company Ltd. (SPARC) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Sun Pharma Advanced Research Company Ltd.?
Sun Pharma Advanced Research Company Ltd. operates in the Pharma sector with a market capitalisation of ₹562,071.4L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.